Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania explains how new agents being studied will be integrated into clinical practice for the treatment of advanced HCC at the 2017 Annual Meeting Annual Meeting in Chicago, IL.